Nordic Nanovector ASA has announced that Luigi Costa will step down as chief executive officer by mutual agreement with the board following a further delay in the development of its key product Betalutin. A search for a new CEO will begin immediately. Nordic Nanovector said that to ensure a smooth transition, Costa had agreed to be available to the board until the end of July 2018. Luigi Costa said: “Nordic Nanovector has recently taken a significant hit to its market valuation and credibility with the Norwegian investment community. As CEO, I have to take full responsibility for this."
Kenneth Newman has resigned from his position as Chief Medical Officer at Verona Pharma PLC to pursue other opportunities, effective April 30. The company has begun the search for...